CFX-1 sm
Cystic Fibrosis

CFX-1 has produced promising results in the standard cellular assays for CF, demonstrating excellent cytotoxicity coupled with a dramatic inhibition of IL-8, a key inflammatory mediator in CF. CFX-1 will target the underlying inflammatory causes of CF pathophysiology and aims to provide a safe, chronic treatment to CF patients that will reduce pulmonary inflammation and mucus secretion and provide for improved breathing and quality of life. CFX-1 is currently designed as an inhaled drug but an oral formulation will also be explored.